| Autor: |
Carla Kuon, MD, Rae Wannier, MPH, David Sterken, MD, Margaret C. Fang, MD, MPH, Jeffrey Wolf, MD, Priya A. Prasad, PhD, MPH |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 4, Iss 6, Pp 792-800 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2542-4548 |
| DOI: |
10.1016/j.mayocpiqo.2020.06.005 |
| Popis: |
Objectives: To evaluate the safety of antimotility agents (AAs) in a population of patients with hematologic malignancies and concurrent Clostridioides difficile infection (CDI) and to describe the outcomes of AA use in a hospital setting. Patients and Methods: We used the electronic health record to identify patients who were hospitalized in the adult malignant hematology service who had 1 or more toxin-positive C difficile stool assay between April 1, 2012, and September 21, 2017. We reviewed medical charts to obtain information on the use of AAs and any subsequent gastrointestinal complications. Results: There were 339 patients who were stool toxin positive for CDI during the study period. Of those, 94 patients (27%) were prescribed AAs within 14 days of CDI diagnosis. All patients received CDI antimicrobial therapy within the first 24 hours. There were 2 adverse gastrointestinal events in the group that received AAs and 6 in the group that did not receive AAs. The risk of adverse events did not differ between patients who received AAs and those who did not (adjusted odds ratio, 0.36; 95% CI, 0.06 to 2.10). The mean age of the full cohort was 52.7±15.5 years, and the mean length of stay was 26.7±22.6 days. Early AA use ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
